EUVIMEDEUVIMED entdecken
LeitlinieÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

AISF-SIMIT practice guidance on treatment of hepatitis d virus (HDV): A 2025 update

Associazione Italiana per lo Studio del Fegato (AISF) and Società Italiana di Malattie Infettive e Tropicali (SIMIT)

Digestive and Liver Disease · 2026

DOI: 10.1016/j.dld.2025.12.017 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Digestive and Liver Disease, 2026. Verfasst von Associazione Italiana per lo Studio del Fegato (AISF) and Società Italiana di Malattie Infettive e Tropicali (SIMIT). Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis D, Chronic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hepatitis Delta virus (HDV) infection represents the most severe form of viral hepatitis, characterized by accelerated progression to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. For decades, Pegylated Interferon (PegIFNα) has been the only therapeutic option, with limited efficacy and poor tolerability. The approval of the HBV/HDV entry inhibitor Bulevirtide marked a turning point, by providing the first anti-HDV specific antiviral drug. This position paper, developed jointly by the Italian Association for the Study of the Liver (AISF) and the Italian Society of Infectious and Tropical Diseases (SIMIT), updates prior national guidance by providing practical recommendations for diagnosis, staging, and treatment of chronic HDV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis D, ChronicHumansHepatitis Delta VirusInterferon-alphaDibenzocycloheptenesPolyethylene GlycolsLipopeptidesLiver CirrhosisItalyRecombinant Proteins

Stichwörter der Autor:innen

BulevirtideChronic hepatitis deltaCirrhosisHDV RNAHepatitis D virusPegIFNVirological response

Substanzen

Antiviral AgentsInterferon-alphabulevirtideDibenzocycloheptenesPolyethylene GlycolsLipopeptidesRecombinant Proteins

Zitieren

APA

Associazione Italiana per lo Studio del Fegato (AISF) and Società Italiana di Malattie Infettive e Tropicali (SIMIT) (2026). AISF-SIMIT practice guidance on treatment of hepatitis d virus (HDV): A 2025 update. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.12.017

Vancouver

Associazione Italiana per lo Studio del Fegato (AISF) and Società Italiana di Malattie Infettive e Tropicali (SIMIT). AISF-SIMIT practice guidance on treatment of hepatitis d virus (HDV): A 2025 update. Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2025.12.017

BibTeX
@article{AssociazioneItalianaperloStudiodelFegatoAISFandSocietItalianadiMalattieInfettiveeTropicaliSIMIT2026,
  author = {Associazione Italiana per lo Studio del Fegato (AISF) and Società Italiana di Malattie Infettive e Tropicali (SIMIT), Associazione Italiana per lo Studio del Fegato (AISF) and Società Italiana di Malattie Infettive e Tropicali (SIMIT)},
  title = {AISF-SIMIT practice guidance on treatment of hepatitis d virus (HDV): A 2025 update},
  journal = {Digestive and Liver Disease},
  year = {2026},
  doi = {10.1016/j.dld.2025.12.017}
}
Kostenlos starten →